TauroLock™ is suitable for central venous access within hemodialysis and oncology. Its dual effectiveness prevents catheter infections and clot formation.
4% citrate (anti-clotting effect), 1.35% taurolidine (broad antimicrobial activity incl. MRSA and VRE) and 100 units of heparin per ml (extra anticoagulant effect)
4% citrate (anti-clotting effect), 1.35% taurolidine (broad antimicrobial activity incl. MRSA and VRE) and 500 units of heparin per mL (extra anticoagulant effect)
